[Table/Fig-4]:
Risk estimates of various factors.
| Quartiles | ||||||||
|---|---|---|---|---|---|---|---|---|
| Variable | 1st | 2nd | 3rd | 4th | p-value from χ2 test for trend | Odds Ratio (95% CI) † | ||
| IGF-I | SIL | N (%)* | 1 (3.2) | 5 (16.1) | 6 (19.3) | 19 (61.2) | 0.008 | 3.94 (1.24-12.56) |
| Control | N (%) | 8 (25.8) | 8 (25.8) | 8 (25.8) | 7 (22.5) | |||
| IGF-II | SIL | N (%) | 1 (3.2) | 3 (9.6) | 7 (22.5) | 20 (64.5) | 0.003 | 4.57 (1.42-14.7) |
| Control | N (%) | 8 (25.8) | 8 (25.8) | 8 (25.8) | 7 (22.5) | |||
| IGFBP-3 | SIL | N (%) | 6 (19.3) | 6 (19.3) | 14 (45.1) | 5 (16.1) | 0.30 | 0.56 (01.61-1.96) |
| Control | N (%) | 8 (25.8) | 8 (25.8) | 7 (22.5) | 8 (25.8) | |||
| C-peptide | SIL | N (%) | 13 (41.9) | 10 (32.2) | 4 (12.9) | 4 (12.9) | 0.31 | 1.74 (0.55-5.46)‡ |
| Control | N (%) | 8 (25.8) | 8 (25.8) | 7 (22.5) | 8 (25.8) | |||
| MR-1 | SIL | N (%) | 2 (6.4) | 5 (16.1) | 6 (19.3) | 18 (58.1) | 0.02 | 3.74 (1.17-11.96) |
| Control | N (%) | 8 (25.8) | 8 (25.8) | 8 (25.8) | 7 (22.5) | |||
| MR-2 | SIL | N (%) | 1 (3.2) | 2 (6.4) | 6 (19.3) | 22 (70.9) | 0.001 | 5.15 (1.58-16.77) |
| Control | N (%) | 8 (25.8) | 8 (25.8) | 7 (22.5) | 8 (25.8) | |||
| CMR | SIL | N (%) | 1 (3.2) | 3 (9.6) | 3 (9.6) | 24 (77.4) | 0.001 | 7.5 (2.17-25.9) |
| Control | N (%) | 8 (25.8) | 8 (25.8) | 7 (22.5) | 8 (25.8) | |||
| BEMR | SIL | N (%) | 1 (3.2) | 2 (6.4) | 2 (6.4) | 26 (83.8) | <0.001 | 12.18 (3.13-47.39) |
| Control | N (%) | 8 (25.8) | 8 (25.8) | 7 (22.5) | 8 (25.8) | |||
*N (%); Number (Percentage), †OR for 4th quartile with IQR as ref. ‡OR for 1st quartile with IQR as ref.